Remarkably, in both the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial and the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, improvements in Lp(a) plasma levels have been associated with significant reductions in ASCV events regardless of LDL-C [49]. Here, LPA is linked to acute coronary syndrome.